{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T14:30:45Z","timestamp":1786113045891,"version":"build-2736575974"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,11]]},"DOI":"10.1097\/01.inf.0000242929.95258.69","type":"journal-article","created":{"date-parts":[[2006,10,23]],"date-time":"2006-10-23T05:39:05Z","timestamp":1161581945000},"page":"1044-1048","source":"Crossref","is-referenced-by-count":29,"title":["Ritonavir\u2013Fluticasone Interaction Causing Cushing Syndrome in HIV-Infected Children and Adolescents"],"prefix":"10.1097","volume":"25","author":[{"given":"Renata","family":"Arrington-Sanders","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Hutton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George K.","family":"Siberry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-11-20210202","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1056\/NEJMoa011157","article-title":"Pediatric AIDS Clinical Trials Group Protocol 219 Team. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1.","volume":"345","author":"Gortmaker","year":"2001","journal-title":"N Engl J Med"},{"key":"R2-11-20210202","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/S0140-6736(98)08468-2","article-title":"Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: A cohort study.","volume":"353","author":"Carr","year":"1999","journal-title":"Lancet"},{"key":"R3-11-20210202","doi-asserted-by":"crossref","first-page":"S135","DOI":"10.1086\/313854","article-title":"HIV protease inhibitor-related lipodystrophy syndrome.","volume":"30","author":"Carr","year":"2000","journal-title":"Clin Infect Dis"},{"key":"R4-11-20210202","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1097\/00002030-200112070-00009","article-title":"Highly active antiretroviral-treated HIV-infected children show fat distribution changes even in absence of lipodystrophy.","volume":"15","author":"Brambilla","year":"2001","journal-title":"AIDS"},{"key":"R5-11-20210202","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1592\/phco.21.9.861.34555","article-title":"Lipodystrophy syndrome in children infected with human immunodeficiency virus.","volume":"21","author":"Wedekind","year":"2001","journal-title":"Pharmacotherapy"},{"key":"R6-11-20210202","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1097\/00002030-200009290-00008","article-title":"Clinical and metabolic presentation of the lipodystrophic syndrome in HIV-infected children.","volume":"14","author":"Jaquet","year":"2000","journal-title":"AIDS"},{"key":"R7-11-20210202","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/00126334-200105010-00005","article-title":"Lipodystrophy in HIV-infected children is associated with high viral load and low CD4+-lymphocyte count and CD4+-lymphocyte percentage at baseline and use of protease inhibitors and stavudine.","volume":"27","author":"Arpadi","year":"2001","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R8-11-20210202","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1086\/342562","article-title":"Exogenous Cushing syndrome mimicking human immunodeficiency virus lipodystrophy.","volume":"35","author":"Gupta","year":"2002","journal-title":"Clin Infect Dis"},{"key":"R9-11-20210202","first-page":"274","article-title":"Cushing's syndrome and severe adrenal suppression in patients treated with ritonavir and inhaled nasal fluticasone.","volume":"75","author":"Chen","year":"1999","journal-title":"Sex Transm Infect"},{"key":"R10-11-20210202","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1097\/00002030-199909100-00038","article-title":"Ritonavir-induced Cushing's syndrome in a patient treated with inhaled fluticasone.","volume":"13","author":"Hillebrand-Haverkort","year":"1999","journal-title":"AIDS"},{"key":"R11-11-20210202","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1445-5994.2004.00723.x","article-title":"Exogenous glucocorticoid excess as a result of ritonavir\u2013fluticasone interaction.","volume":"35","author":"Soldatos","year":"2005","journal-title":"Intern Med J"},{"key":"R12-11-20210202","first-page":"149","article-title":"Peyri\u00e8re H, Mauboussin JM, Vincent D. Cushing's syndrome in a patient treated by ritonavir\/lopinavir and inhaled fluticasone HIV.","volume":"4","author":"Rouanet","year":"2003","journal-title":"Medicine"},{"key":"R13-11-20210202","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1053\/jinf.2001.0928","article-title":"Iatrogenic Cushing's syndrome in an HIV-infected patient treated with inhaled corticosteroids (fluticasone propionate) and low dose ritonavir enhanced PI containing regimen.","volume":"44","author":"Clevenbergh","year":"2002","journal-title":"J Infect"},{"key":"R14-11-20210202","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.jpeds.2005.11.034","article-title":"Cushing syndrome with secondary adrenal insufficiency from concomitant therapy with ritonavir and fluticasone.","volume":"148","author":"Johnson","year":"2006","journal-title":"J Pediatr"},{"key":"R15-11-20210202","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/j.1552-4604.1998.tb04398.x","article-title":"Protease inhibitors as inhibitors of human cytochromes P450: High risk associated with ritonavir.","volume":"38","author":"Von Moltke","year":"1998","journal-title":"J Clin Pharmacol"},{"key":"R16-11-20210202","first-page":"2005","article-title":"Iatrogenic Cushing's syndrome with osteoporosis and secondary adrenal failure in HIV infected patients receiving inhaled corticosteroids and ritonavir-boosted protease inhibitors: six cases.","author":"Samaras","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"R18-11-20210202","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1378\/chest.117.2.593","article-title":"Asthma and Cushing's syndrome.","volume":"117","author":"Wilson","year":"2000","journal-title":"Chest"},{"key":"R19-11-20210202","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.ecl.2005.01.013","article-title":"Exogenous Cushing's syndrome and glucocorticoid withdrawal.","volume":"34","author":"Hopkins","year":"2005","journal-title":"Endocrinol Metab Clin N Am"},{"key":"R20-11-20210202","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1086\/517681","article-title":"Cushing's syndrome induced by megestrol acetate in a patient with AIDS.","volume":"27","author":"Padmanabhan","year":"1998","journal-title":"Clin Infect Dis"},{"key":"R21-11-20210202","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/S0022-3476(99)70467-1","article-title":"Adrenal suppression in children with the human immunodeficiency virus treated with megestrol acetate.","volume":"134","author":"Stockheim","year":"1999","journal-title":"J Pediatr"},{"key":"R22-11-20210202","doi-asserted-by":"crossref","first-page":"16","DOI":"10.5070\/D33NS8X0T5","article-title":"Cushing's syndrome secondary to topical glucocorticoids.","volume":"9","author":"Joe","year":"2003","journal-title":"Dermatol Online J"},{"key":"R23-11-20210202","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1046\/j.1365-2265.2003.18021.x","article-title":"Cushing's syndrome secondary to topical corticosteroids abuse.","volume":"58","author":"Ermis","year":"2003","journal-title":"Clin Endocrinol"},{"key":"R24-11-20210202","first-page":"1","article-title":"National Asthma Education and Prevention Program. Key clinical activities for quality asthma care. Recommendations of the national Asthma Education and Prevention program.","volume":"52","author":"Williams","year":"2003","journal-title":"MMWR Recomm Rep"},{"key":"R25-11-20210202","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s002280050407","article-title":"Pharmacokinetic and pharmacodynamic evaluation of fluticasone propionate after inhaled administration.","volume":"53","author":"Mollmann","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"R26-11-20210202","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1001\/archinte.159.16.1903","article-title":"Effects of high-dose inhaled corticosteroids on plasma cortisol concentrations in healthy adults.","volume":"159","author":"Brus","year":"1999","journal-title":"Arch Intern Med"},{"key":"R28-11-20210202","article-title":"Physicians\u2019 Desk Reference, 59th ed.","year":"2004"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00006454-200611000-00011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T16:49:24Z","timestamp":1785948564000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00006454-200611000-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,11]]},"references-count":26,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2006]]}},"URL":"https:\/\/doi.org\/10.1097\/01.inf.0000242929.95258.69","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2006,11]]}}}